In recent years, the recognition of FOXM1’s pivotal role in driving tumor progression, metastasis, drug resistance, and growth in solid tumors has sparked considerable interest in developing small molecule inhibitors targeting FOXM1 for potential therapeutic applications in patients with solid cancers [46,58,89,90,91,92,93,94,95]. Here, FOXM1 is linked to neoplasm.